The COVID-19 has created CDMO fever in the global biotech industry. In order to seize the market opportunity of US$242.64 billion by 2026, the CDMO (Contract Development and Manufacturing Services) industry has set off a wave of investment and mergers and acquisitions, and the Biotechnology and Pharmaceutical Industry Development Ordinance, which will come into force in 2022, will even include CDMOs in the rental tax incentives. Taiwan's semiconductor industry already has a protector, TSMC, and Taiwan's biotech industry is following the same pattern, hoping to create another protector of the biotech industry with CDMO, which is considered to be the next star of tomorrow, and has attracted biomedical companies to scramble for a position. The CDMO is considered to be the next star of tomorrow and has attracted biomedical practitioners to compete for the position.